Geron Secures $375 Million for RYTELO’s Blood Cancer Treatment Launch and Expansion

Geron Corporation has announced a new financing arrangement, raising up to $375 million to support the commercialization of RYTELO, a first-in-class telomerase inhibitor for blood cancers. Through partnerships with Royalty Pharma and Pharmakon Advisors, Geron secured $250 million immediately and could receive an additional $125 million in debt financing. Royalty Pharma’s portion is structured as a synthetic royalty agreement based on RYTELO’s U.S. sales, while Pharmakon Advisors contributed a senior secured loan.

The funds will allow Geron to advance RYTELO’s launch in the U.S. and potentially in Europe, continue clinical trials, and enhance its supply chain. According to Geron’s CFO, Michelle Robertson, this strategic financing with strong industry partners underscores RYTELO’s commercial promise and provides flexibility for further growth initiatives in hematologic cancers, including completing the Phase 3 IMpactMF trial for relapsed/refractory myelofibrosis.

Royalty Pharma and Pharmakon Advisors both expressed enthusiasm for Geron’s innovative approach, highlighting RYTELO’s potential impact on patients with limited treatment options in hematologic malignancies. The agreement reflects Royalty Pharma’s confidence in RYTELO’s sales potential and Pharmakon’s support for Geron’s European expansion and further clinical development.